A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.

What are the side effects of Semaglutide?

Reported side effects of Semaglutide include: Nausea (common, usually transient), Vomiting, Diarrhea, Constipation, Abdominal pain, Headache, Fatigue, Injection site reactions, Hypoglycemia (with insulin/sulfonylureas), Gallbladder problems, Pancreatitis, Acute kidney injury, BOXED WARNING: Thyroid C-cell tumors - contraindicated with MTC/MEN 2.

What is the typical dosing for Semaglutide?

Prescribed doses per FDA labeling. Common doses observed in research: 0.25mg weekly (starting), 0.5mg weekly, 1mg weekly, 2.4mg weekly (Wegovy max). Duration: Long-term / chronic use. Administration: Subcutaneous injection weekly, or oral (Rybelsus).

Weight Loss

Semaglutide

Also known as: Ozempic, Wegovy, Rybelsus

FDA Approved

Popular For

Weight loss, appetite control, blood sugar management

Key Facts: Semaglutide

Category: Weight Loss
FDA Status: FDA Approved
Clinical Status: FDA Approved - T2D, weight loss, CV risk, kidney protection; Oral Wegovy approved Dec 2025
Administration: Subcutaneous injection weekly, or oral (Rybelsus)
Typical Dose: 1-2.4 mg weekly (after titration)
Frequency: Once weekly
Evidence Level: FDA Approved
Duration: Long-term / chronic use

Also Known As

Ozempic, Wegovy, Rybelsus

Mechanism of Action

Semaglutide mimics the GLP-1 hormone, slowing gastric emptying, increasing insulin secretion, reducing glucagon release, and acting on brain appetite centers to reduce hunger and increase satiety. It has 94% amino acid similarity to human GLP-1.

Research Summary

STEP trials: 15-17% weight loss. FLOW trial: 24% reduction in kidney disease progression (Jan 2025 approval). Wegovy pill: 16.6% weight loss (Dec 2025 approval). Oral Rybelsus approved for CV risk reduction (Oct 2025).

Clinical Status:FDA Approved - T2D, weight loss, CV risk, kidney protection; Oral Wegovy approved Dec 2025

Trial Progress:FDA Approved

Pre

III

FDA

FDA Approval Studies

This peptide is FDA approved. Below are the key clinical trials that supported its approval.

STEP Program (Semaglutide Treatment Effect in People with obesity)

Novo Nordisk • Phase 3

Approved 2021

Participants:

4,500+ participants across STEP 1-4 trials

Duration:

68 weeks

Primary Endpoint:

Percent change in body weight from baseline

Key Results:

✓STEP 1: 14.9% average weight loss vs 2.4% placebo
✓STEP 2 (with diabetes): 9.6% weight loss vs 3.4% placebo
✓STEP 3 (with lifestyle intervention): 16.0% weight loss
✓STEP 4: Continued treatment maintained weight loss vs regain with placebo

View Study

SUSTAIN Program (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes)

Novo Nordisk • Phase 3

Approved 2017

Participants:

8,000+ participants across SUSTAIN 1-10 trials

Duration:

30-104 weeks

Primary Endpoint:

HbA1c reduction from baseline

Key Results:

✓Superior HbA1c reduction vs comparators (sitagliptin, exenatide, dulaglutide)
✓Significant cardiovascular benefit shown in SUSTAIN-6
✓26% reduction in major cardiovascular events
✓Consistent weight loss of 4-6 kg across trials

View Study

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical DosingⓘDoses commonly used by people in practice, based on community reports and anecdotal experience.

Community experience

Common Dose

1-2.4 mg weekly (after titration)

Range

0.25-2.4 mg weekly

Frequency

Once weekly

Titrate up slowly over 16-20 weeks to minimize GI side effects. Start at 0.25 mg, increase every 4 weeks. Many stay at 1 mg if tolerating well.

Research DosingⓘDoses from published scientific studies and clinical trials. May include human or animal research.

Scientific studies

Prescribed doses per FDA labeling

Doses from Studies

0.25mg weekly (starting)

FDA Label - Ozempic/Wegovy - Initial dose for all patients ↗

0.5mg weekly

STEP 1 Trial, NEJM 2021 - Dose escalation step ↗

1.0mg weekly

SUSTAIN Trials - T2D maintenance dose ↗

2.4mg weekly (max)

STEP 1 Trial, NEJM 2021 - Weight management target dose - 14.9% weight loss ↗

Duration

Long-term / chronic use

Administration

Subcutaneous injection weekly, or oral (Rybelsus)

Timing & Administration

Best Time to Take

Morning, same day each week

Once weekly, same day and time

Food Recommendation

With or without food

Why This Timing?

Weekly injection should be at a consistent time. Morning allows monitoring for any side effects during waking hours.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

●Nausea (common, usually transient)
●Vomiting
●Diarrhea
●Constipation
●Abdominal pain
●Headache
●Fatigue
●Injection site reactions
●Hypoglycemia (with insulin/sulfonylureas)
●Gallbladder problems
●Pancreatitis
●Acute kidney injury
●BOXED WARNING: Thyroid C-cell tumors - contraindicated with MTC/MEN 2

References

Related Peptides

Peptides commonly compared with Semaglutide or used in similar applications.

Tirzepatide

FDA

A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.

Weight Loss

Retatrutide

Clinical Trials

A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.

Weight Loss

AOD-9604

Clinical Trials

A modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full GH.

Weight Loss

Liraglutide

FDA

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.

Weight Loss

Cagrilintide

Clinical Trials

A long-acting amylin analog developed by Novo Nordisk for obesity treatment. Works through a different mechanism than GLP-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. Shows enhanced weight loss when combined with semaglutide (CagriSema).

Weight Loss

Dulaglutide

FDA

An FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.

Weight Loss

How to Use Semaglutide Semaglutide Alternatives Compare with Similar Browse All Peptides

Looking for a trusted vendor?

Pro members get access to verified vendors with quality standards & exclusive discount codes.

View Verified Vendors

PRO

Want updates on Semaglutide research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Back to all peptides